- Home
- »
- Meetings
- »
- Industry/Academia Translational Oncology Symposium 2012
- »
- PAK Inhibitors for Cancer – Trailblazing a Path to the Clinic
PAK Inhibitors for Cancer – Trailblazing a Path to the Clinic
David Campbell, PhD, Afraxis
| 14 minutes | |
| David Campbell | |
Prior to Afraxis, Dr. Campbell served as a member of the Phenomix Corporation executive team since 2003, most recently as an executive officer and senior vice president, discovery and development with responsibility for all drug discovery and development thru early clinical development to proof of concept in humans. Dr. Campbell was the senior vice president of chemical sciences at ActivX Biosciences from 2001 to 2003, where he directed the company's internal drug discovery programs as well as the development of ActivX's activity-based chemical probes. Dr. Campbell was director of discovery chemistry at Bayer Corporation where he directed the research efforts of the 41-scientist group discovering and optimizing drugs in the cancer, obesity, osteoporosis, and diabetes therapeutic areas. Dr. Campbell began his career at Affymax Research Institute, a combinatorial chemistry company that was creating novel technologies and strategies to facilitate the identification and optimization of compounds for the treatment of cancer and immune-mediated diseases.
Dr. Campbell holds three sole-authored and fifteen jointly authored patents, and has co-authored 30 original papers. He conducted post-doctoral studies at the University of California, Berkeley after receiving a Ph.D. in organic chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College.
